Betrixaban Proven Cost-Effective in Treatment for Venous Thromboembolism

A study presented at ASHP 2018 Midyear Clinical Meeting & Exhibition compared the cost-effectiveness of betrixaban to enoxaparin in patients presenting with venous thromboembolism (VTE.) 

“VTE in hospitalized acute medically ill patients is a leading preventable cause of morbidity and mortality,” said W. Richey Neuman of Portola Pharmaceuticals, Inc. “Studies show that VTE risk continues following discharge in non-surgical acutely ill patients receiving short-duration VTE prophylaxis.”

The study explained, “A cost-effectiveness analysis was conducted to estimate the cost per quality-adjusted life-year (QALY) gained for betrixaban (35-42 days) compared to standard-duration enoxaparin  (6-14 days) from a US payer perspective over a lifetime horizon.”

Results showed the betrixaban dominated enoxaparin with savings of $780 and increased QALYs of 0.017 per patient. 

“The corresponding probabilistic analysis showed that VTE prophylaxis with betrixaban led to a saving of $790 and a gain of 0.017 QALYs per patient. Furthermore, all sensitivity analyses maintained the result of the betrixaban dominating enoxaparin, ” said Mr Neuman.

“Due to cost savings per patient and unmet need, betrixaban can be considered a cost-effective treatment for adult non-surgical patients with acute medical illness at risk of VTE, who require extended prophylaxis from hospitalization through post-discharge.”

—Edan Stanley